A new citrate-free formulation of Taltz® (ixekizumab) has been made available by Eli Lilly.

Taltz, an interleukin-17A antagonist, is approved for the treatment of adults and children 6 years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy; adults with active psoriatic arthritis; adults with active ankylosing spondylitis; and adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation.

Findings from a phase 1 crossover study evaluating pain intensity following injection in healthy individuals (ClinicalTrials.gov Identifier: NCT03848403) showed that the new citrate-free formulation of ixekizumab was associated with significantly less injection site pain (as measured by the Visual Analog Scale [VAS] pain score) when compared with the original formulation (least-squares mean difference of VAS scores between the original and citrate-free formulation, − 21.7; P < .0001).

In another phase 1 study (ClinicalTrials.gov Identifier: NCT04259346), the citrate-free formulation of ixekizumab was found to be bioequivalent to the original. The safety profile of the new formulation was reported to be consistent with the original formulation as well.

Taltz is supplied as 80mg of ixekizumab per mL in a single-dose prefilled autoinjector or syringe. The citrate-free formulation is being shipped across the US; broad availability of the new formulation is expected by the end of the month.

References

  1. Lilly’s Taltz® (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience. News release. Eli Lilly and Company. Accessed August 8, 2022. https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-site-pain-for-improved-patient-experience-301601067.html
  2. Chabra S, Gill BJ, Gallo G, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Advances in Therapy. Published online April 21, 2022. Accessed August 8, 2022.
  3. Taltz. Package insert. Eli Lilly and Company; 2022. Accessed August 8, 2022. https://uspl.lilly.com/taltz/taltz.html#pi